Hormone replacement therapy poses a risk of death
According to the largest study ever, hormone replacement therapy (HRT) is responsible for more than 1,000 British women suffering from ovarian cancer and death since 1991.
HRT is used by millions of women to relieve menopausal symptoms or help women maintain their youth longer. But research by Professor Valerie Beral and colleagues at Oxford University proves that people who use HRT for 5 years or more are more likely to die from a deadly cancer.
According to the study, people taking HRT will increase the risk of breast cancer and breast cancer. The risk of breast cancer is highest with 20,000 cases over the past 10 years, the work report by Professor Beral said. However, when women do not use HRT anymore, the risk of cancer is no longer available.
"My personal opinion is that using HRT too long is not good because the risk increases over time, especially breast cancer," Professor Beral said. The study involved 1.3 million British women in their 50s from 1996 to 2001. These people answered questions about lifestyle, social class and time to use HRT.
This is the largest study in the world in this area, and the results show that for every 2,500 women with one person with ovarian cancer if using HRT for a long time and every 3,300 people have one death from the disease.
Regular exercise is the therapy that doctors recommend women to
do instead of using hormone stimulants. (Winston's artwork)
Phuong Lien
- Alternative hormone therapy can affect hearing
- Alzheimer's can be treated with gene replacement therapy
- Asian spices reduce the risk of breast cancer
- New discovery of hormone therapy for prostate cancer
- Men also .. 'menopause'
- Hormone anti-aging can shorten the life of people
- Breast cancer is related to hormone replacement therapy
- The process of changing the body when injecting transgender hormones
- Hormone - 'not an anti-aging fairy drug'
- The US may approve a technique to create a 3-parent child
- 'Hormone darkness' and diabetes
- Women are prone to postmenopausal cancer